

Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

May 21, 2013

LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:

| Name | For | Withheld |
|---------------------|-------------|-----------------|
| Ronald H. Farmer | 235,731,934 | 1,964,748 |
| Robert A. Ingram | 233,865,876 | 3,830,806 |
| Theo Melas-Kyriazi | 237,081,508 | 615,174 |
| G. Mason Morfit | 235,623,283 | 2,073,399 |
| J. Michael Pearson | 232,521,825 | 5,174,857 |
| Robert N. Power | 235,168,850 | 2,527,832 |
| Norma A. Provencio | 237,125,741 | 570,941 |
| Howard B. Schiller | 221,521,559 | 16,175,123 |
| Lloyd M. Segal | 236,082,529 | 1,614,153 |
| Katharine Stevenson | 234,501,146 | 3,195,536 |

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2014 annual meeting of shareholders; and approved the continuance of the Company from the Canada Business Corporations Act to the British Columbia Business Corporations Act.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be

made available on the Company's web site,

www.valeant.com

.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at

www.valeant.com

.

Contact Information:

Laurie W. Little

949-461-6002

laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

